Elotuzumab as a novel anti-myeloma immunotherapy
Treatment of multiple myeloma has undergone significant change in the last decade with the introduction of new immunomodulatory agents, proteasome inhibitors, and immunotherapeutic approaches. Elotuzumab is a humanized monoclonal antibody targeting CS1, which is a member of the SLAM (Signaling Lymph...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2017-08-01
|
| Series: | Human Vaccines & Immunotherapeutics |
| Subjects: | |
| Online Access: | http://dx.doi.org/10.1080/21645515.2017.1327487 |
| _version_ | 1797677575321944064 |
|---|---|
| author | Sabarinath Venniyil Radhakrishnan Neelam Bhardwaj Mary Steinbach Janet Weidner Tim Luetkens Djordje Atanackovic |
| author_facet | Sabarinath Venniyil Radhakrishnan Neelam Bhardwaj Mary Steinbach Janet Weidner Tim Luetkens Djordje Atanackovic |
| author_sort | Sabarinath Venniyil Radhakrishnan |
| collection | DOAJ |
| description | Treatment of multiple myeloma has undergone significant change in the last decade with the introduction of new immunomodulatory agents, proteasome inhibitors, and immunotherapeutic approaches. Elotuzumab is a humanized monoclonal antibody targeting CS1, which is a member of the SLAM (Signaling Lymphocyte Activation Molecule) family of proteins, expressed on the surface of myeloma plasma cells. Here we review the preclinical investigations that led to the development of elotuzumab and the clinical studies that resulted in its approval for the treatment of relapsed/refractory multiple myeloma. Although preclinical data looked very promising, elotuzumab monotherapy did not result in objective clinical responses in patients with relapsed/refractory multiple myeloma. However, combination treatment with immunomodulators and proteasome inhibitors resulted in substantial clinical activity in relapsed/refractory MM. Currently, there are several clinical trials ongoing investigating the role of elotuzumab in newly diagnosed myeloma patients and in patients receiving maintenance therapy. |
| first_indexed | 2024-03-11T22:47:15Z |
| format | Article |
| id | doaj.art-d2a991a1f37b4da79d72b7147d0575b3 |
| institution | Directory Open Access Journal |
| issn | 2164-5515 2164-554X |
| language | English |
| last_indexed | 2024-03-11T22:47:15Z |
| publishDate | 2017-08-01 |
| publisher | Taylor & Francis Group |
| record_format | Article |
| series | Human Vaccines & Immunotherapeutics |
| spelling | doaj.art-d2a991a1f37b4da79d72b7147d0575b32023-09-22T08:17:50ZengTaylor & Francis GroupHuman Vaccines & Immunotherapeutics2164-55152164-554X2017-08-011381751175710.1080/21645515.2017.13274871327487Elotuzumab as a novel anti-myeloma immunotherapySabarinath Venniyil Radhakrishnan0Neelam Bhardwaj1Mary Steinbach2Janet Weidner3Tim Luetkens4Djordje Atanackovic5Hematology and Hematologic Malignancies, University of Utah / Huntsman Cancer InstituteHematology and Hematologic Malignancies, University of Utah / Huntsman Cancer InstituteHematology and Hematologic Malignancies, University of Utah / Huntsman Cancer InstituteHematology and Hematologic Malignancies, University of Utah / Huntsman Cancer InstituteHematology and Hematologic Malignancies, University of Utah / Huntsman Cancer InstituteHematology and Hematologic Malignancies, University of Utah / Huntsman Cancer InstituteTreatment of multiple myeloma has undergone significant change in the last decade with the introduction of new immunomodulatory agents, proteasome inhibitors, and immunotherapeutic approaches. Elotuzumab is a humanized monoclonal antibody targeting CS1, which is a member of the SLAM (Signaling Lymphocyte Activation Molecule) family of proteins, expressed on the surface of myeloma plasma cells. Here we review the preclinical investigations that led to the development of elotuzumab and the clinical studies that resulted in its approval for the treatment of relapsed/refractory multiple myeloma. Although preclinical data looked very promising, elotuzumab monotherapy did not result in objective clinical responses in patients with relapsed/refractory multiple myeloma. However, combination treatment with immunomodulators and proteasome inhibitors resulted in substantial clinical activity in relapsed/refractory MM. Currently, there are several clinical trials ongoing investigating the role of elotuzumab in newly diagnosed myeloma patients and in patients receiving maintenance therapy.http://dx.doi.org/10.1080/21645515.2017.1327487antibodiescs1elotuzumabimmunotherapymonoclonalmultiple myelomaslam family of receptors |
| spellingShingle | Sabarinath Venniyil Radhakrishnan Neelam Bhardwaj Mary Steinbach Janet Weidner Tim Luetkens Djordje Atanackovic Elotuzumab as a novel anti-myeloma immunotherapy Human Vaccines & Immunotherapeutics antibodies cs1 elotuzumab immunotherapy monoclonal multiple myeloma slam family of receptors |
| title | Elotuzumab as a novel anti-myeloma immunotherapy |
| title_full | Elotuzumab as a novel anti-myeloma immunotherapy |
| title_fullStr | Elotuzumab as a novel anti-myeloma immunotherapy |
| title_full_unstemmed | Elotuzumab as a novel anti-myeloma immunotherapy |
| title_short | Elotuzumab as a novel anti-myeloma immunotherapy |
| title_sort | elotuzumab as a novel anti myeloma immunotherapy |
| topic | antibodies cs1 elotuzumab immunotherapy monoclonal multiple myeloma slam family of receptors |
| url | http://dx.doi.org/10.1080/21645515.2017.1327487 |
| work_keys_str_mv | AT sabarinathvenniyilradhakrishnan elotuzumabasanovelantimyelomaimmunotherapy AT neelambhardwaj elotuzumabasanovelantimyelomaimmunotherapy AT marysteinbach elotuzumabasanovelantimyelomaimmunotherapy AT janetweidner elotuzumabasanovelantimyelomaimmunotherapy AT timluetkens elotuzumabasanovelantimyelomaimmunotherapy AT djordjeatanackovic elotuzumabasanovelantimyelomaimmunotherapy |